Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Treating mixed dyslipidemias: why and how.

C M Ballantyne1

  • 1Section of Atherosclerosis, Baylor College of Medicine, Houston, Texas 77030, USA. cmb@bcm.tmc.edu

Clinical Cardiology
|July 11, 2001
PubMed
Summary

Patients with low HDL-C and high triglycerides face high cardiovascular risk. Statins and fibrates show potential benefits, with combination therapy improving lipid profiles but raising concerns about cost and side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of allele-specific KIV-2 repeats and impact on Lp(a) measurements for cardiovascular disease risk.

bioRxiv : the preprint server for biology·2023
Same author

Longitudinal increases in blood biomarkers of inflammation or cardiovascular disease and the incidence of venous thromboembolism.

Journal of thrombosis and haemostasis : JTH·2018
Same author

Intermuscular and perimuscular fat expansion in obesity correlates with skeletal muscle T cell and macrophage infiltration and insulin resistance.

International journal of obesity (2005)·2015
Same author

Metabolic syndrome risk for cardiovascular disease and diabetes in the ARIC study.

International journal of obesity (2005)·2008
Same author

Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy.

Current medical research and opinion·2007
Same author

Glutamic acid decarboxylase antibodies are indicators of the course, but not of the onset, of diabetes in middle-aged adults: the Atherosclerosis Risk in Communities Study.

Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas·2007

Area of Science:

  • Cardiology
  • Metabolic Disorders
  • Pharmacology

Background:

  • Patients with mildly elevated low-density lipoprotein cholesterol (LDL-C) but low high-density lipoprotein cholesterol (HDL-C) and/or high triglycerides are at increased risk for cardiovascular disease (CVD).
  • Dyslipidemia, characterized by abnormal lipid levels, is a significant risk factor for atherosclerosis and related cardiovascular events.

Purpose of the Study:

  • To review the efficacy of lipid-lowering therapies, including statins, fibrates, and combination treatments, in managing dyslipidemia and reducing cardiovascular risk.
  • To evaluate the impact of these therapies on low high-density lipoprotein cholesterol (HDL-C) and triglyceride levels in at-risk patients.

Main Methods:

  • Literature review of clinical trials and studies investigating the effects of statins, fibrates, and combination therapies on lipid profiles and cardiovascular outcomes.
  • Analysis of data concerning patients with mixed dyslipidemias, specifically focusing on low HDL-C and elevated triglycerides.

Main Results:

  • Statins have demonstrated effectiveness in slowing coronary heart disease (CHD) progression and reducing CHD events, particularly in patients with low HDL-C.
  • Fibrate trials have yielded mixed results regarding their benefit in patients with low HDL-C.
  • Combination therapy with statins and fibrates or niacin effectively improves the overall lipid profile, including HDL-C and triglycerides.

Conclusions:

  • Statins are beneficial for patients with low HDL-C and mixed dyslipidemias.
  • Combination therapy offers comprehensive lipid profile improvement but necessitates consideration of increased costs and potential side effects.
  • Further research may be warranted to optimize combination therapy strategies for cardiovascular risk reduction.

Related Experiment Videos